HLX316 is a potential first-in-class glyco-editing biologic developed using Palleon's EAGLE platform. It is constructed by fusing a human-derived sialidase enzyme with a human anti-B7-H3 monoclonal antibody. By targeting B7-H3-expressing tumor cells, this agent drives their desialylation, thereby reversing glycosylation-mediated immune suppression within the tumor microenvironment.

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.